Treatment of diseases or disorders using placental stem cells

• US 9,149,569 B2
• Filed: 05/16/2011
• Issued: 10/06/2015
• Est. Priority Date: 12/06/2000
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US13/108,871
• Publication Number:
  US 20110217271A1
• Time in Patent Office: 1,604 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A01N 1/021 Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 : Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12M 29/10 : Perfusion
• CPC Class Codes: C12M 47/04 : Cell isolation or sorting purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04
• CPC Class Codes: C12N 2509/00 : Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2510/02 : Cells for production
• CPC Class Codes: C12N 2533/90 : Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0603 : Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0647 : Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources

Abstract

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Claims

1. A method of repairing heart tissue in an individual that has suffered from myocardial infarction, comprising administering to the individual a therapeutically effective amount of isolated human placental stem cells, wherein said placental stem cells are:

OCT-4⁺, CD34⁻

, CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH3⁺, SH4⁺, SSEA3⁻

, and/or SSEA4⁻

, wherein OCT-4 is octamer binding protein 4;

OCT-4⁺, CD34⁻

, SSEA3⁻

and SSEA4⁻

;

OCT-4⁺ and CD34⁻

, and additionally SH3⁺ or SH4⁺;

or

CD34⁻

and one or more of CD29⁺, CD45⁻

, CD90⁺, SH2⁺, SH3⁺, SH4⁺, or MHC Class II⁻

.

2. The method of claim 1, wherein said placental stem cells are OCT-4⁺, CD34⁻

, CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH3⁺, SH4⁺, SSEA3⁻

, and SSEA4⁻

.

3. The method of claim 1, wherein said placental stem cells are OCT-4⁺, CD34⁻

, SSEA3⁻

and SSEA4⁻

.

4. The method of claim 3, wherein said placental stem cells are additionally SH3⁺ or SH4⁺.

5. The method of claim 3, wherein said placental stem cells are additionally SH3⁺ and SH4⁺.

6. The method of claim 3, wherein said placental stem cells are additionally CD29⁺, CD45⁻

, CD90⁺, SH2⁺, SH3⁺, SH4⁺, or MHC Class II⁻

.

7. The method of claim 3, wherein said placental stem cells have at least one of the following additional characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SSEA3⁻

, or SSEA4⁻

.

8. The method of claim 3, wherein said placental stem cells have at least the following additional characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SSEA3⁻

, and SSEA4⁻

.

9. The method of claim 3, wherein said placental stem cells have at least one of the following additional characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, or CD90⁺.

10. The method of claim 3, wherein said placental stem cells have at least the following additional characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, and CD90⁺.